Fig. 4
From: Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease
Risk differences for discontinuations and dose reductions due to adverse events. The risk differences were assessed before and after placebo-adjustment. Negative risk difference favors deutetrabenazine. p-values comparing the risk differences between deutetrabenazine and tetrabenazine were obtained from z-tests. AE = adverse event